12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
Status:
Terminated
Trial end date:
2018-03-12
Target enrollment:
Participant gender:
Summary
This 12-month open-label study will provide further information regarding the long-term
safety and tolerability of intepirdine (RVT-101) for subjects with Alzheimer's disease who
have completed the double-blind, placebo-controlled, lead-in study RVT-101-3001 (double-blind
study).